References of "Revue Médicale de Liège"
     in
Bookmark and Share    
Peer Reviewed
See detailExercice physique et sport: du meilleur au pire.
Scheen, André ULg; Kulbertus, Henri ULg

in Revue Médicale de Liège (2001), 56(4), 193-4

Detailed reference viewed: 40 (1 ULg)
Peer Reviewed
See detailEffets benefiques de l'activite physique sur les facteurs de risque cardio-vasculaire.
Scheen, André ULg; Paquot, Nicolas ULg

in Revue Médicale de Liège (2001), 56(4), 239-43

Numerous observational (epidemiological surveys) or interventional (controlled trials) studies demonstrated that regular physical activity increases insulin sensitivity in normal subjects and decreases ... [more ▼]

Numerous observational (epidemiological surveys) or interventional (controlled trials) studies demonstrated that regular physical activity increases insulin sensitivity in normal subjects and decreases insulin resistance in patients with obesity and/or type 2 diabetes. These favourable effects are at least partially linked to a reduction in abdominal fat mass. This results in a significant improvement of lipid profile, with a decrease in the concentrations of total cholesterol, LDL cholesterol and triglycerides, associated with an increase of HDL cholesterol level. Such favourable metabolic effects related to regular physical activity probably explain the better cardiovascular prognosis observed in regularly exercising subjects as compared to sedentary individuals. These observations should motivate any practitioner to promote endurance physical exercise in every subject, especially in individuals at high cardiovascular risk. [less ▲]

Detailed reference viewed: 74 (3 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le celecoxib (Celebrex).
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(1), 53-5

Celecoxib (Celebrex, Pharmacia) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as nonsteroidal anti-inflammatory drug (NSAID). Its current indications are ... [more ▼]

Celecoxib (Celebrex, Pharmacia) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as nonsteroidal anti-inflammatory drug (NSAID). Its current indications are osteoarthritis and rheumatoid arthritis. The usual recommended daily dosage of celecoxib is 200 mg (in one or two intakes per day), to be increased up to 400 mg (two intakes per day) if necessary. Its clinical efficacy seems to be similar to that of other NSAIDs. However, its safety profile, especially gastro-intestinal tolerance and perhaps renal safety, is much better because of the COX-2 selectivity. [less ▲]

Detailed reference viewed: 30 (0 ULg)
Peer Reviewed
See detailL'etude clinique du mois. Apres la tempete sur les anorexigenes centraux, l'etude "STORM" avec la sibutramine.
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(1), 56-8

The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized. This clinical trial (open label for the first ... [more ▼]

The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized. This clinical trial (open label for the first 6 months and double blind versus placebo for a further 18 months) demonstrates the positive effect of sibutramine, a new anorectic drug, on long-term weight maintenance after weight loss in obese subjects. The benefit of sibutramine on the cardiovascular risk profile of the obese patient is more particularly discussed. [less ▲]

Detailed reference viewed: 18 (0 ULg)
Peer Reviewed
See detailEtude clinique du mois. Protection secondaire de l'accident vasculaire cerebral par le perindopril: l'etude PROGRESS.
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(11), 792-5

PROGRESS ("Perindopril pROtection aGainst REcurrent Stroke Study") demonstrated that blood-pressure lowering treatment with perindopril, an angiotensin converting enzyme inhibitor (combined with the ... [more ▼]

PROGRESS ("Perindopril pROtection aGainst REcurrent Stroke Study") demonstrated that blood-pressure lowering treatment with perindopril, an angiotensin converting enzyme inhibitor (combined with the diuretic agent indapamide when necessary), reduces the risk of stroke by 28% (95% CI: 17-38, p < 0.0001) among patients with a history of stroke or transient ischaemic attack. This protective effect was observed among both hypertensive and non-hypertensive individuals. It was more marked in the patients receiving combined perindopril + indapamide treatment (-43%; 95% CI 30-54) who were those who showed the greatest reduction in arterial blood pressure (-12/5 mm Hg). According to these observations, the authors concluded that treatment with these two agents should now be considered routinely for patients with a history of stroke or transient ischaemic attack, irrespective of their blood pressure. [less ▲]

Detailed reference viewed: 38 (3 ULg)
Peer Reviewed
See detailResponsabilité pénale et faute pénale
Boxho, Philippe ULg

in Revue Médicale de Liège (2001), 56

Detailed reference viewed: 31 (2 ULg)
Peer Reviewed
See detailLa chirurgie du thymus normal, involué ou tumoral
Limet, Raymond ULg; Rogister, Bernard ULg

in Revue Médicale de Liège (2001), 55

Detailed reference viewed: 21 (2 ULg)
Peer Reviewed
See detailLe cas clinique du mois. L'histoire naturelle d'une obesite morbide: aller vers le diabete de type 2 insulinorequerant et retour apres chirurgie bariatrique.
De Flines, Jenny ULg; Letiexhe, Michel ULg; Desaive, Claude ULg et al

in Revue Médicale de Liège (2001), 56(12), 816-22

Morbid obesity is a crucial risk factor in the development of type 2 diabetes and is often associated with a metabolic syndrome closely linked to insulin resistance. This case report illustrates the ... [more ▼]

Morbid obesity is a crucial risk factor in the development of type 2 diabetes and is often associated with a metabolic syndrome closely linked to insulin resistance. This case report illustrates the natural history of morbid obesity, starting during the adolescence and ending with an extremely severe type 2 diabetes at the age of 40. Numerous attempts of weight loss with various medical approaches failed and diabetes mellitus rapidly became insulin-requiring in a context of extreme insulin resistance. Finally, the patient was submitted to a gastric bypass which resulted in a drastic weight loss over 50 kg during the year following surgery without any significant side-effects or complications. Type 2 diabetes almost disappeared and the classical markers of insulin resistance were markedly improved. This clinical case clearly demonstrates that successful management of obesity with bariatric surgery can reverse severe type 2 diabetes. [less ▲]

Detailed reference viewed: 156 (1 ULg)
Peer Reviewed
See detailInfo-congres. Prevention pharmacologique de la progression de la diminution de la tolerance au glucose vers le diabete de type 2: effets favorables de la metformine et de l'acarbose.
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(10), 727-30

We report the positive results of two large prospective studies of pharmacological prevention of type 2 diabetes presented at the EASD Congress in Glasgow, September 12, 2001. In the "Diabetes Prevention ... [more ▼]

We report the positive results of two large prospective studies of pharmacological prevention of type 2 diabetes presented at the EASD Congress in Glasgow, September 12, 2001. In the "Diabetes Prevention Program", metformin (2 x 850 mg/day), a biguanide compound, reduces the progression from impaired glucose tolerance towards type 2 diabetes by 31% (p < 0.001) while in the "STOP-NIDDM trial", acarbose (3 x 100 mg/day), an alpha-glucosidase inhibitor, diminished it by 24% (p < 0.002). These results are, however, less marked than those obtained with lifestyle modifications including better dietary habits and increased physical exercise (-58% versus control group, p < 0.001). [less ▲]

Detailed reference viewed: 15 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. La sibutramine (Reductil).
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(9), 656-9

Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity. It is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which exerts its ... [more ▼]

Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity. It is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which exerts its effects in vivo predominantly via its secondary and primary amine metabolites. Sibutramine is indicated as an adjunctive therapy within a weight management programme in patients with obesity (BMI > or = 30 kg/m2) or in overweight subjects (BMI > or = 27 kg/m2) if other eight-related risk factors are present (dyslipidaemias, diabetes mellitus). In those patients with an inadequate response on initial dose of 10 mg per day (suggested as less than 2 kg weight loss in four weeks), the dose may be increased to 15 mg once daily, providing that sibutramine is well tolerated. Several large-scale randomized clinical trials demonstrated the efficacy of long-term (at least one year) treatment with sibutramine in obese subjects with or without type 2 diabetes. Sibutramine was also shown to help in maintaining long-term weight reduction. Most frequent side-effects are dry mouth and constipation, as well as mild increase in heart rate and arterial blood pressure. The impact of sibutramine on cardiovascular morbidity and mortality of obese nondiabetic and diabetic patients will be studied soon in a large international prospective clinical trial. [less ▲]

Detailed reference viewed: 84 (2 ULg)
Peer Reviewed
See detailLe Finapres, une technique performante pour evaluer l'hypotension orthostatique, la neuropathie autonome et la syncope vaso-vagale.
Scheen, André ULg; Geronooz, I.; Marchand, Monique ULg

in Revue Médicale de Liège (2001), 56(8), 577-82

Finapres is a device able to continuously and non invasively measure arterial blood pressure by photoplethysmography in the finger. It can be used in various dynamic tests which involve cardiocirculatory ... [more ▼]

Finapres is a device able to continuously and non invasively measure arterial blood pressure by photoplethysmography in the finger. It can be used in various dynamic tests which involve cardiocirculatory adjustments, as a passive posture test ("tilt test") or an active orthostatic test (from squatting to standing position in the so-called squatting test). It represents a valuable help in the diagnosis of orthostatic hypotension (of endogenous or iatrogenic origin), of autonomic neuropathy (secondary to diabetes mellitus or to a neurological disease) or of vasovagal syncope. All these conditions are characterized by a defect of arterial and venous vasoconstriction and by an insufficient reflex tachycardia because of autonomic dysfunction. [less ▲]

Detailed reference viewed: 118 (7 ULg)
Peer Reviewed
See detailInfo-congres. Insulinotherapie pour prevenir le diabete de type 1 chez des sujets apparentes a haut risque: resultats negatifs du "Diabetes Prevention Trial-Type 1".
Scheen, André ULg; Philips, Jean-Christophe ULg

in Revue Médicale de Liège (2001), 56(7), 536-8

The results of the American multicentre "Diabetes Prevention Trial-Type 1" were presented by J. Skyler during the last congress of the American Diabetes Association in Philadelphia on June 23, 2001. The ... [more ▼]

The results of the American multicentre "Diabetes Prevention Trial-Type 1" were presented by J. Skyler during the last congress of the American Diabetes Association in Philadelphia on June 23, 2001. The prophylactic subcutaneous administration of low-dose insulin was not able to prevent the development of type 1 diabetes nor to preserve residual insulin secretion in young relatives at very high-risk of diabetes (> 50% in the next 5 years), selected upon genetic, immunological and metabolic criteria. [less ▲]

Detailed reference viewed: 34 (0 ULg)
Peer Reviewed
See detailL'image du mois. L'hypotension orthostatique filmee par le Finapres: neuropathie autonome versus cause iatrogene.
Scheen, André ULg; Descampheleire, M.; Marchand, Monique ULg

in Revue Médicale de Liège (2001), 56(3), 133-4

Detailed reference viewed: 38 (0 ULg)
Peer Reviewed
See detailLe cas clinique du mois. Syndrome d'hypertension porto-pulmonaire associe a une hypoxemie severe.
Kolan, C.; Ghuysen, Alexandre ULg; Lambermont, Bernard ULg et al

in Revue Médicale de Liège (2001), 56(8), 543-7

We report the case of a patient with liver cirrhosis who was admitted to the emergency room for rapid occurrence of dyspnea and severe hypoxemia at rest. Lung CT-scan and echocardiography did not disclose ... [more ▼]

We report the case of a patient with liver cirrhosis who was admitted to the emergency room for rapid occurrence of dyspnea and severe hypoxemia at rest. Lung CT-scan and echocardiography did not disclose any right-to-left shunt and right-sided heart catheterization evidenced major precapillary pulmonary hypertension. The present feature supports the hypothesis that the pulmonary complications of cirrhosis, the hepatopulmonary syndrome and the portopulmonary hypertension, which are usually considered as mutually exclusive, may coexist. In such circumstances, the right failing heart is the major determinant to the immediate prognosis. [less ▲]

Detailed reference viewed: 51 (4 ULg)
Full Text
Peer Reviewed
See detailComment je traite une ascite
Gielen, S.; Delwaide, Jean ULg; Detry, Olivier ULg et al

in Revue Médicale de Liège (2001), 56(12), 809-815

Ascites is the most common of the major complications of cirrhosis. The initial evaluation of a patient with ascites should include a history, physical evaluation and some investigations. Treatment should ... [more ▼]

Ascites is the most common of the major complications of cirrhosis. The initial evaluation of a patient with ascites should include a history, physical evaluation and some investigations. Treatment should consist of treating the underlying liver disease, sodium restricted diet (2 g of Na+/day) and diuretics. This regimen is effective in 90 % of patients. The treatment options for the diuretic-resistant patients include serial therapeutic paracentesis, peritoneovenous shunting, TIPSand liver transplantation. The treatment and prophylaxis of spontaneous bacterial peritonitis which is a frequent and severe complication in cirrhotic patients with ascites is also important. The differential diagnosis with secondary bacterial peritonitisis is essential because the latter usually does not resolve unless patients are surgically treated. [less ▲]

Detailed reference viewed: 91 (4 ULg)
Full Text
Peer Reviewed
See detailComment j'explore ... une myopathie par biopsie musculaire
Deprez, Manuel ULg

in Revue Médicale de Liège (2001), 56(1), 49-52

Muscle biopsy is a valuable tool in the diagnosis of many neuromuscular disorders. It is an invasive investigation that will be considered after careful clinical examination, supplemented by biological ... [more ▼]

Muscle biopsy is a valuable tool in the diagnosis of many neuromuscular disorders. It is an invasive investigation that will be considered after careful clinical examination, supplemented by biological and electrophysiological studies. The biopsy procedure and the subsequent processing of specimen in the laboratory significantly influence the information provided by the microscopic examination of muscle tissue. They are reviewed in details in this article. Close collaboration between clinicians and neuropathologists in the setting of an optimized procedure will further increase the diagnostic yield of muscle biopsy. [less ▲]

Detailed reference viewed: 66 (8 ULg)
Peer Reviewed
See detailLes thyroïdites auto-immunes
Geenen, Vincent ULg; Warzee, Emmanuelle ULg; Legros, Jean-Jacques ULg

in Revue Médicale de Liège (2001), 56

Detailed reference viewed: 28 (4 ULg)
Peer Reviewed
See detailL'etude clinique du mois. L'etude CALM ou interet de combiner un inhibiteur de l'enzyme de conversion et un antagoniste du recepteur de type 1 de l'angiotensine II dans le traitement de la nephropathie diabetique.
Philips, Jean-Christophe ULg; Weekers, Laurent ULg; Scheen, André ULg

in Revue Médicale de Liège (2001), 56(2), 126-8

The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme ... [more ▼]

The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme inhibitor (ACE-I) and an angiotensin II type 1 receptor blocker--in patients with type 2 diabetes, high blood pressure and microalbuminuria. The study included 200 patients randomized to receive candesartan 16 mg or lisinopril 20 mg for 12 weeks, followed by 12 weeks of the same monotherapy or a combination treatment. Main outcomes are the reduction of microalbuminuria and blood pressure. All three of the treatments are effective, but the dual blockade is respectively 18%, 8 mmHg and 5 mmHg more effective in reducing microalbuminuria, systolic and diastolic blood pressure. No comparison is made between this "new" association and the more frequently used biotherapy (i.e. ACE-I plus thiazidic diuretic) and therefore its usefulness in regular practice is still to be determined. [less ▲]

Detailed reference viewed: 177 (0 ULg)